Article Text
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Q In postmenopausal women, does oestrogen plus progestogen hormone therapy increase the risk of abnormal mammographic results and diagnosis of breast cancer?
METHODS
Design:
randomised, placebo controlled trial (Women’s Health Initiative).
Allocation:
concealed.
Blinding:
blinded (clinicians, participants, data collectors, outcome assessors, and monitoring committee).
Follow up period:
mean 5.6 years.
Setting:
40 US clinical centres.
Patients:
16 608 postmenopausal women who were 50–79 years of age (mean age 63 y). Exclusion criteria: previous hysterectomy, breast cancer, or probable survival <3 years.
Interventions:
1 daily tablet of conjugated equine oestrogen, …
Footnotes
A modified version of this abstract appears in ACP Journal Club.
For correspondence: Dr R T Chlebowski, Harbor-UCLA Research and Education Institute, Torrance, CA, USA. rchlebowskirei.edu
Sources of funding: National Heart, Lung and Blood Institute and Wyeth-Ayerst Research Laboratories.